Stock prices for Alexza Pharmaceuticals Inc. recently surged by 25% to 78 cents. This came after the Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee conditionally backed the drugmaker’s plan to sell an inhaled antipsychotic drug. Adusave is approved for people with schizophrenia and bipolar mania. However, the panel’s 9-8 vote was contingent on the company using a risk mitigation plan proposed by the FDA.
